European research trends in nuclear medicine

  • Ann Nucl Med. 2018 Nov;32(9):579-582. doi: 10.1007/s12149-018-1303-7.
Masayuki Inubushi  1 ,  Mitsuaki Tatsumi  2 ,  Yuka Yamamoto  3 ,  Katsuhiko Kato  4 ,  Tetsuya Tsujikawa  5 ,  Ryuichi Nishii  6
Affiliations
  • 1. Division of Nuclear Medicine, Department of Radiology, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan. [email protected].
  • 2. Department of Radiology, Osaka University Hospital, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • 3. Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
  • 4. Department of Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, 1-20, Daikominami 1-chome, Higashi-ku, Nagoya, Aichi, 461-8673, Japan.
  • 5. Biomedical Imaging Research Center, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji-cho, Fukui, 910-1193, Japan.
  • 6. Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences (NIRS), QST, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan.
PMID: 30242670 DOI: 10.1007/s12149-018-1303-7
Abstract

Written by associate editors of the Annals of Nuclear Medicine, this invited review article is intended to offer our readers a condensed global view on the high-quality research work that has been published in Europe last year. We have divided this article into five sections. The first three sections from the oncology category include "[18F]fluorodeoxyglucose (FDG) positron-emission tomography (PET) for therapy monitoring in malignant lymphoma", "[18F]fluoromisonidazole (FMISO) PET for hypoxia", and "lymphoscintigraphy update". It is followed by a section on "amyloid PET for Alzheimer's disease" using [11C]Pittsburgh Compound B (PiB) and [18F]florbetapir from the neurology category. The final section reviews three original articles in the field of "basic and translational molecular imaging" regardless of the category, which investigated new PET tracers such as L-4-borono-2-[18F]fluoro-phenylalanine (FBPA), O-(2-[18F]fluoroethyl)-L-tyrosine (FET) and 64Cu-NOTA-pertuzumab in small Animals. We hope that this review article will arouse greater interest in our readers in recent European research trends in the field of nuclear medicine.

Keywords
Amyloid PET; Hypoxia PET; Rodents; Sentinel lymph node biopsy; Treatment response.